Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system

Characteristics and trends of PCSK9 inhibitor prescription fills in the United States

(2021) Sharon Attipoe-Dorcoo et al.   Journal of Clinical Lipidology

Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis

(2020) Paul Guedeney et al.   European Heart Journal-Cardiovascular Pharmacotherapy

PCSK9 Inhibition, Atherosclerotic Cardiovascular Disease and Health Economics: Challenges at the Crossroads

(2019) Lieven Annemans et al.   Journal of Clinical Lipidology

2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   ATHEROSCLEROSIS

P5367Indirect comparison of the safety and efficacy of alirocumab and evolocumab: from a comprehensive meta-analysis of 30 randomized controlled trials

(2019) P Guedeney et al.   EUROPEAN HEART JOURNAL

Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia

(2019) Michael J. Koren et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDL-Cholesterol

(2018) Zhao-Peng Liu et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction

(2017) Maria-Corina Serban et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials

(2017) Aris Karatasakis et al.   Journal of the American Heart Association

PCSK9 Inhibitors

(2016) Pradeep Natarajan et al.   CELL

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance

(2016) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab

(2016) Marian McDonagh et al.   Journal of Managed Care & Specialty Pharmacy

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

(2015) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data

(2014) Arrigo FG Cicero et al.   Expert Opinion On Drug Safety

New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs

(2013) Giuseppe Danilo Norata et al.   EUROPEAN HEART JOURNAL

Data Mining of the Public Version of the FDA Adverse Event Reporting System

(2013) Toshiyuki Sakaeda et al.   International Journal of Medical Sciences

Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin‐Treated Subjects From 3 Data Sources: A Retrospective Analysis

(2013) Peter H. Jones et al.   Journal of the American Heart Association

Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations

(2012) Toshiyuki Sakaeda et al.   International Journal of Medical Sciences